EDDING announced that the applications for drug approval of VASCEPA® have been officially accepted in Mainland China

Our vision is to become a leading pharmaceutical company focusing on three core therapeutic areas, namely anti-infectives, cardiovascular disease (‘CVD') and respiratory system, by leveraging our full value chain capabilities.


We believe our drug asset sourcing track record, advanced manufacturing facility, international supply chain management capabilities and MNC-caliber senior management team, together with our in-depth local market insights, scaled local commercial platform, localized manufacturing facilities and local operating track record, position us well to further strengthen our competitive advantages in the pharmaceutical industry in China.

Learn more

We have established a diversified product portfolio comprising six core products. 

Learn more

We are one of the few domestics pharmaceutical companies in China that possess advanced quality management, manufacturing and international supply chain management capabilities.

Learn more
Commercial Operation

We have a well-established sales and marketing system with a proven track record. Our professional marketing and operational team and efficient data-driven operations enhance the accessibility of critical medical products and enable more patients to benefit from both our branded-products and innovative drugs.

Leveraging our deep market insights, we have been able to successfully identify and acquire or in-license high quality products that address unmet medical needs in China. We are committed to building an integrated drug research and development platform which focuses primarily on three core therapeutic areas: anti-infective, CVD and respiratory system.

Learn more
Unit 122-129, Building A3 No.700, Wanrong Road,Shanghai

publication@eddingpharm.com

沪ICP备2021007464号

Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038